

WHAT IS CLAIMED IS:

1. A method of treating inflammatory bowel disease (IBD) in a patient in need thereof which comprises orally administering to the patient an effective amount of a pooled human polyclonal immunoglobulin preparation.
- 5 2. The method according to Claim 1 wherein the inflammatory bowel disease is ulcerative colitis (UC).
3. The method according to Claim 1 wherein the inflammatory bowel disease is Crohn's disease.
4. A method of treating mucosal inflammation which comprises orally 10 administering to a patient suffering from said mucosal inflammation an effective amount of a pooled human polyclonal immunoglobulin preparation.
5. The method according to any one of Claims 1-4 wherein the immunoglobulin is at least one of immunoglobulin G (IgG), immunoglobulin A (IgA) or a mixture of immunoglobulin G (IgG) and immunoglobulin A (IgA).
- 15 6. The method according to any one of Claims 1-4 wherein the immunoglobulin preparation is dispersed in a pharmaceutically acceptable carrier.
7. The method according to any one of Claims 1-4 wherein the amount of immunoglobulin administered to said patient is from about 0.5 to 1.5 grams at least once a day.
- 20 8. The method according to any one of Claims 1-4 wherein the immunoglobulin is enterically coated.
9. A method of treating inflammatory bowel disease (IBD) in a patient in need thereof which comprises orally administering to the patient a pooled human polyclonal immunoglobulin preparation comprising at least about 25% IgG polyclonal antibodies.
- 25 10. A method of treating mucosal inflammation which comprises orally administering to a patient suffering from said mucosal inflammation a pooled human polyclonal immunoglobulin preparation comprising at least about 25% IgG polyclonal antibodies.
11. A method of treating inflammatory bowel disease (IBD) in a patient in need 30 thereof which comprises orally administering to the patient a pooled human polyclonal

immunoglobulin preparation comprising at least about 30% to about 85% IgG, about 5% to about 30% IgA and about 1% to about 25% IgM polyclonal antibodies.

12. A method of treating mucosal inflammation which comprises orally administering to a patient suffering from said mucosal inflammation a pooled human 5 polyclonal immunoglobulin preparation comprising at least about 85% IgG, about 5% to about 30% IgA and about 1% to about 25% IgM polyclonal antibodies.